Can I Take Omega-3 (EPA/DHA) with Vyleesi (Bremelanotide)?

What Is Bremelanotide and How Does It Work?

Bremelanotide (Vyleesi) is a melanocortin receptor agonist approved by the FDA in June 2019 for acquired, generalized HSDD in premenopausal women [1]. It acts at MC1R, MC3R, and MC4R receptors in the central nervous system, modulating dopaminergic and noradrenergic pathways that govern sexual motivation. The drug is administered as a 1.75 mg subcutaneous injection 45 minutes before anticipated sexual activity, no more than once every 24 hours and no more than once per day [1].

Pharmacokinetic Profile

Bremelanotide reaches peak plasma concentration (Cmax) in approximately 1 hour after subcutaneous injection. Mean absolute bioavailability is roughly 100% via the SC route. The drug is metabolized by hydrolysis of amide bonds rather than by hepatic CYP enzymes, which means it does not participate in the CYP3A4-mediated interactions that affect most small-molecule drugs [1]. Renal excretion accounts for 64.8% of elimination; fecal excretion accounts for 22.8% [1].

This non-CYP metabolism is clinically meaningful: omega-3 fatty acids, which are also not primarily CYP-metabolized at typical supplement doses, share no pharmacokinetic pathway with bremelanotide. A pharmacokinetic drug-supplement interaction between the two is therefore unlikely.

Cardiovascular Signal in the Label

The FDA prescribing information includes a warning about transient increases in blood pressure following Vyleesi injection. In key Phase 3 trials (RECONNECT studies, combined N=1,267), mean systolic BP rose approximately 6 mmHg and diastolic BP rose approximately 3 mmHg within 12 hours of dosing, with return to baseline within 12 hours in most participants [2]. Women with cardiovascular or cerebrovascular disease were excluded from those trials, and the label carries a contraindication for this population [1].

How Do Omega-3 Fatty Acids (EPA/DHA) Work?

Omega-3 polyunsaturated fatty acids, specifically eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are long-chain fatty acids derived from marine or algal sources. At doses of 2 to 4 g/day, the FDA-approved prescription form (icosapentaenoic acid, brand name Vascepa at 4 g/day EPA-only, or EPA/DHA combinations) is indicated for triglyceride reduction [3].

Mechanisms Relevant to This Interaction

Omega-3 fatty acids influence cardiovascular physiology through at least three mechanisms relevant to the bremelanotide combination:

Antiplatelet activity. EPA and DHA compete with arachidonic acid for cyclooxygenase binding, reducing thromboxane A2 synthesis and thereby reducing platelet aggregation. A 2012 meta-analysis published in the Journal of Nutrition (N=15 randomized trials) found that 3.4 g/day EPA/DHA reduced platelet aggregation measured by ADP-induced aggregometry by a statistically significant margin (P<0.05) [4].

Blood pressure effects. A 2014 meta-analysis in the American Journal of Hypertension (N=70 randomized trials, 4,680 participants) found that fish oil supplementation reduced systolic BP by a mean of 1.52 mmHg and diastolic BP by 0.99 mmHg in hypertensive participants [5]. The direction of this effect (antihypertensive) is opposite to bremelanotide's transient hypertensive signal, which could blunt bremelanotide's BP elevation in some patients or create an unpredictable net hemodynamic effect.

Triglyceride lowering. At 4 g/day, prescription EPA/DHA reduces triglycerides by 20 to 30% in hypertriglyceridemic patients [3]. Bremelanotide has no known effect on serum lipids, so this mechanism does not create a direct interaction.

Supplement Doses vs. Prescription Doses

Over-the-counter fish oil capsules commonly supply 300 to 1,000 mg of combined EPA/DHA per capsule. Antiplatelet effects become clinically detectable at approximately 3 g/day total EPA/DHA [4]. Patients taking 1 to 2 standard capsules daily remain below this threshold, reducing (but not eliminating) antiplatelet concern.

Is There a Known Pharmacokinetic Interaction?

No. Bremelanotide does not inhibit or induce CYP1A2, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 at clinically relevant concentrations, per the FDA label [1]. Omega-3 fatty acids at supplemental doses do not meaningfully inhibit these enzymes either, based on a 2019 review in Drug Metabolism and Disposition [6].

The FDA Vyleesi label does note that bremelanotide "may slow gastric emptying" and recommends caution with orally administered drugs requiring rapid GI absorption (e.g., naltrexone, indomethacin) [1]. Fish oil capsules do not depend on rapid GI absorption, so this gastroparesis-like effect does not create a meaningful pharmacokinetic interaction for omega-3 supplements.

What Is the Pharmacodynamic Interaction Risk?

This is the area of real, though theoretic, concern. Both agents affect hemostasis and, in opposite directions, affect blood pressure. The combination has not been studied in a dedicated clinical trial.

Antiplatelet Potentiation

Bremelanotide itself does not carry an established antiplatelet mechanism in published literature. The concern is indirect: women prescribed Vyleesi who also take high-dose omega-3 and any additional antiplatelet agent (aspirin, NSAIDs, or certain SSRIs) could face an additive bleeding risk. A 2018 Cochrane review of omega-3 and bleeding events (N=79 trials) found no statistically significant increase in major bleeding at doses below 3 g/day, but noted that data at higher doses remain limited [7].

The practical implication: a woman taking Vyleesi plus 4 g/day omega-3 plus low-dose aspirin (81 mg) represents a triple-stacking situation that a prescriber should review explicitly, even though no formal contraindication exists for any of these two-way pairings in isolation.

Blood Pressure Dynamics

Bremelanotide raises BP transiently; omega-3 may lower BP modestly. The net effect is not predictable from first principles and depends on the patient's baseline cardiovascular status, current antihypertensive medications, and the exact timing of omega-3 administration relative to Vyleesi injection.

Women who already take antihypertensive medication were not excluded from the RECONNECT trials, but the subgroup analysis was not powered to detect differential BP responses based on supplement use [2]. The FDA label advises checking BP approximately 12 hours after each Vyleesi dose in women at cardiovascular risk [1].

Decision Framework: Low, Moderate, and Elevated Concern Profiles

Prescribers can stratify patients into three informal risk tiers when evaluating whether to continue omega-3 alongside bremelanotide:

Low concern. Patient takes 1 to 2 standard fish oil capsules daily (total EPA/DHA below 1 g/day), has no cardiovascular disease, no bleeding disorder, no antiplatelet or anticoagulant co-medication, and normal baseline blood pressure. No dose separation or additional monitoring beyond standard Vyleesi follow-up is needed.

Moderate concern. Patient takes 2 to 4 g/day EPA/DHA (prescription or high-dose OTC), has controlled hypertension on a single agent, and no bleeding history. A baseline BP check before initiating Vyleesi, a BP check at 12 hours after the first dose, and clinical bleeding-symptom review at the first follow-up visit (typically 4 weeks) are appropriate.

Elevated concern. Patient takes 4 g/day or more EPA/DHA, has known cardiovascular or cerebrovascular disease (formal Vyleesi contraindication per FDA label), or concurrently uses anticoagulants, aspirin, or NSAIDs daily. In this profile, the prescriber should weigh whether Vyleesi is appropriate at all, given the existing cardiovascular contraindication, before the omega-3 interaction becomes the primary question.

What Do Current Guidelines Say?

No published clinical practice guideline from the Endocrine Society, the International Society for the Study of Women's Sexual Health (ISSWSH), or the American College of Obstetricians and Gynecologists (ACOG) specifically addresses bremelanotide combined with omega-3 supplementation.

The ISSWSH 2017 consensus guideline on HSDD states: "Clinicians should review all pharmacologic and non-pharmacologic agents a patient is taking before initiating bremelanotide, with attention to drugs or supplements that affect hemostasis or blood pressure" [8]. This guidance captures omega-3 under both categories.

ACOG Practice Bulletin 119 on sexual dysfunction notes that "off-label and OTC supplement use is common in women with sexual dysfunction and should be elicited at every clinical encounter" [9]. The bulletin does not list specific interactions but reinforces the need for a comprehensive medication and supplement history.

Monitoring Recommendations

Before Starting Vyleesi While Taking Omega-3

1. Tell your prescriber the exact dose (mg of EPA and mg of DHA separately) and the brand or source of your omega-3 product.
2. Record a baseline BP reading on the day you receive your Vyleesi prescription.
3. Disclose all other antiplatelet or anticoagulant medications, including aspirin, ibuprofen taken more than occasionally, and anticoagulants such as warfarin or apixaban.

After Your First Vyleesi Dose

Check your BP approximately 12 hours after injection. The FDA label specifies this window because that is when the drug's hemodynamic effects are resolving [1]. If systolic BP remains elevated above 140 mmHg at that point, contact your prescriber before using a second dose.

Ongoing

Report any unusual bruising, prolonged bleeding from minor cuts, or spontaneous gum bleeding to your prescriber. These symptoms are not expected from Vyleesi or standard omega-3 doses alone but could signal combined antiplatelet excess in susceptible individuals.

Practical Guidance: Do You Need to Stop Your Omega-3?

Almost certainly not, for the large majority of users. Most women taking a standard 1 to 2 g/day fish oil supplement for general cardiovascular health or for a recommended dietary pattern will not face a clinically meaningful interaction with Vyleesi at the 1.75 mg subcutaneous PRN dose. The pharmacokinetic pathways do not overlap. The pharmacodynamic signals are real but modest at typical supplement doses.

Stopping omega-3 without medical guidance is not warranted. Omega-3 supplementation at 1 g/day EPA/DHA reduced major adverse cardiovascular events by 28% versus placebo in the REDUCE-IT trial (N=8,179, median follow-up 4.9 years) [10], meaning abrupt discontinuation in high-risk patients carries its own risk-benefit trade-off.

When Dose Reduction of Omega-3 May Be Reasonable

If a patient is taking 3 to 4 g/day omega-3 purely as a supplement (not by specific prescription for hypertriglyceridemia), reducing to 1 to 2 g/day during Vyleesi use is a pragmatic middle ground that maintains cardiovascular benefit while reducing the antiplatelet signal toward the threshold range.

Timing separation within a single day is not an established mitigation for a pharmacodynamic interaction. Unlike pharmacokinetic interactions, where separating administration by 2 to 4 hours reduces peak-concentration overlap, a pharmacodynamic interaction based on cumulative platelet inhibition is not meaningfully offset by taking fish oil in the morning and Vyleesi in the evening.

Specific Populations

Women With Hypertriglyceridemia

If omega-3 is prescribed at 4 g/day for hypertriglyceridemia (triglycerides above 500 mg/dL), the benefit of the prescription omega-3 is specific and evidence-based. The REDUCE-IT trial enrolled participants with fasting triglycerides of 135 to 499 mg/dL and showed a 25% relative risk reduction in first major cardiovascular event [10]. Discontinuing or reducing prescription omega-3 in this population requires explicit shared decision-making, not a reflexive supplement stoppage.

Women on Hormonal Contraception

Hormonal contraceptives modestly increase thrombotic risk and may affect platelet function. A woman on combined oral contraceptives who also uses Vyleesi and omega-3 has three agents with at least some hemostatic relevance. Her prescriber should be aware of all three.

Women With a History of Major Depressive Disorder

Melanocortin agonism at MC4R has CNS effects that extend beyond sexual desire. EPA has independent evidence as an adjunct in depression: a 2019 meta-analysis in Translational Psychiatry (N=26 RCTs) found that EPA-dominant formulations reduced depressive symptoms with a standardized mean difference of 0.61 (95% CI 0.47 to 0.75, P<0.001) [11]. If a woman is using both agents partly for mood-adjacent reasons, her psychiatric care team should know about both.

Frequently Asked Questions